SUPN

AI Memo

Supernus

As of 2026-10-17/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-17 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Indivior merger closing • 2026-11-02

Base target: $41 / p=50% prob

Biggest risk

Closing can still be delayed, the share consideration fluctuates with INDV, and integration or debt-funded transaction costs may erode expected benefits. Strong Q2 revenue did not translate into stronger adjusted operating earnings. Merger announcement Q2 earnings exhibit

Invalidation

Break below $30 or thesis failure.

What would change my mind?

Both shareholder approvals remove a major merger hurdle. Supernus reported strong Q2 growth-product sales, while the combination offers scale and potential cost savings if it closes and is integrated successfully. Supernus vote Indivior vote Q2 earnings exhibit

Research note

Recommendation

—

Confidence

medium

As of

2026-10-17

Base target

$41

p=50%

Bull target

$47

p=25%

Bear target

$30

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Growth-product sales versus earnings quality
ONAPGO second-supplier regulatory path
Both shareholder approvals remove a major merger hurdle.

BearKey bullets

Merger closing remains subject to regulatory and customary conditions despite both shareholder votes; the expected November 2 date is not a completion announcement.
ONAPGO second-supplier filing and approval timing remain unconfirmed in the reviewed evidence.
Q2 adjusted operating earnings declined year over year, and a $54.9 million APOKYN impairment contributed to a GAAP operating loss.

WatchKey bullets

Indivior merger closing

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $41 (p=50%)

Target spread vs base: +15% / -27%

Scenario probabilities

Bull Target: $47 (p=25%)Base Target: $41 (p=50%)Bear Target: $30 (p=25%)

Commentary

The October 15 votes improve transaction visibility, but no verified post-vote price reaction or fresh analyst revisions were supplied. The stored September earnings document concerns Addex, not SUPN, and was excluded. Zeroes in quantitative sentiment fields mean unavailable data, not neutral readings. Supernus vote Indivior vote

As of 2026-10-17 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Growth-product sales versus earnings quality
ONAPGO second-supplier regulatory path

Scenarios

Bull Target (Scenario probability)

$47 / p=25% prob

Base Target (Scenario probability)

$41 / p=50% prob

Bear Target (Scenario probability)

$30 / p=25% prob

Analysis 2026-10-17 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-11-02
Indivior merger closing
Supernus stockholders approved the merger on October 15, and Indivior stockholders approved the related share issuance. Indivior expects a November 2 closing, but regulatory and other closing conditions remain; neither vote establishes that the merger has closed. Supernus holders are to receive 1.5401 Indivior shares per share, so the value is not a fixed cash price. [#8-K-2026-10-15] [#SEC-INDV-8K-2026-10-15] Supernus vote Indivior vote Merger terms
Prob 80.00% • Move 6.00% • Priced-in 80.00%

Short-term Catalysts

Next few weeks

Growth-product sales versus earnings quality
2026-12-31
Q2 revenue rose 32% to $219.1 million and revenue from four growth products rose 52% to $175.7 million. Supernus raised 2026 revenue guidance to $860 million–$890 million, yet Q2 adjusted operating earnings fell to $31.2 million from $40.9 million and GAAP results included a $54.9 million APOKYN impairment. Subsequent product sales and margins must validate the higher revenue outlook. [#SEC-8K-2026-08-03] Q2 earnings exhibit
Prob 60% • Move 7% • Priced-in 65%

Long-term Catalysts

Months to a year

ONAPGO second-supplier regulatory path
2027-06-30
Supernus planned an FDA submission for a second ONAPGO supplier in Q3 2026 and described potential approval by mid-2027. The evidence reviewed does not confirm that submission occurred, so timing and supply benefits remain conditional. [#SEC-8K-2026-08-03] Q2 earnings exhibit
Prob 50% • Move 6% • Priced-in 35%

Risks

Merger closing remains subject to regulatory and customary conditions despite both shareholder votes; the expected November 2 date is not a completion announcement.
ONAPGO second-supplier filing and approval timing remain unconfirmed in the reviewed evidence.
Q2 adjusted operating earnings declined year over year, and a $54.9 million APOKYN impairment contributed to a GAAP operating loss. Q2 earnings exhibit
The fixed 1.5401-share exchange ratio exposes SUPN holders to INDV share-price changes; projected merger benefits and integration savings may not materialize.

Peers

Symbol	Summary
AXSM	A closer commercial CNS comparator, but differences in product mix and spending limit direct multiple comparisons. Axsome Q2 release
NBIX	An established commercial neuroscience comparator with a substantially larger sales base; useful for operating context, not a direct valuation multiple. Neurocrine Q2 release

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-17

Loading AI feed…

Symbol

Summary

AXSM

A closer commercial CNS comparator, but differences in product mix and spending limit direct multiple comparisons. Axsome Q2 release

NBIX

An established commercial neuroscience comparator with a substantially larger sales base; useful for operating context, not a direct valuation multiple. Neurocrine Q2 release